文献速递膀胱癌与上尿路尿路上皮癌

强化膀胱内丝裂霉素C化疗消融:非肌层浸润性膀胱癌的新方法

Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2018-10-06

这项前瞻性单中心非随机研究比较了47例接受短期强化膀胱内丝裂霉素C方案(每周3次共2周)的复发非肌层浸润性膀胱癌患者与47例接受经尿道膀胱肿瘤电切术加早期灌注及每周灌注方案的患者。39个月时完全缓解率组1为61.7%、组2为70.2%(p=0.38),无癌生存率无差异,无全身毒性,局部毒性无差异。作者认为该短期强化方案可考虑作为特定患者替代经尿道膀胱肿瘤电切术的治疗策略。

要点

  • 39个月完全缓解率强化组61.7% vs 手术组70.2%(p=0.38),无显著差异。
  • 两组无癌生存率无差异(log-rank <7.82),无全身毒性,局部毒性无差异(p=0.32)。
  • 作者认为短期强化丝裂霉素C方案可考虑替代经尿道膀胱肿瘤电切术用于特定患者。

核心结论

  • 所提出的丝裂霉素C方案具有良好的消融能力,可归因于给药时机与肿瘤细胞倍增速率之间更好的一致性。
  • 短期强化方案可考虑作为特定非肌层浸润性膀胱癌患者替代经尿道膀胱肿瘤电切术的治疗策略。

研究设计与样本

  • 前瞻性、单中心、非随机研究,比较47例(组1)有低至中危非肌层浸润性膀胱癌病史、长无复发间期、复发灶最大直径≤1cm且细胞学阴性的患者与47例连续入组的具有相同基线特征的患者(组2)。
  • 组1接受膀胱内丝裂霉素C每周3次共2周;组2接受经尿道膀胱肿瘤电切术加早期灌注及每周膀胱内丝裂霉素C方案。
  • 所有无癌患者接受每月丝裂霉素C维持治疗;随访包括膀胱定位图、排尿及冲洗尿细胞学、可疑区域电切、原肿瘤位置电切以及超声或计算机断层扫描/磁共振成像。
  • 统计采用χ2检验和Student t检验分别比较分类变量和连续变量,Kaplan-Meier曲线估计无癌生存率,显著性水平设为p<0.05。

主要发现

  • 39个月时完全缓解率组1为61.7%、组2为70.2%(p=0.38)。
  • Kaplan-Meier分析显示总体无癌生存率无差异(log-rank <3.84),各组内按肿瘤大小无差异(log-rank <3.84),组间无差异(log-rank <7.82)。
  • 未观察到全身毒性病例;局部毒性两组间无差异(p=0.32),经对症治疗后缓解,无患者中断治疗。

临床怎么用

  • 作者认为短期强化丝裂霉素C方案可考虑作为特定非肌层浸润性膀胱癌患者替代经尿道膀胱肿瘤电切术的治疗策略。

局限性

  • 患者数量少。
  • 因单中心三级医院导致的选择偏倚。
  • 随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mitomycin C (MMC) is widely used, but the optimal dose and schedule have not been established. OBJECTIVE: To evaluate the ablative power and patient safety of a short-term intensive schedule of intravesical MMC in patients with recurrent non-muscle-invasive bladder cancer (NMIBC). DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, single-center, nonrandomized study that compared 47 patients (group 1) with a history of low- to intermediate-risk NMIBC with long free-recurrence intervals, recurrence of ≤1cm in maximum diameter, and negative cytology to 47 consecutive patients with the same baseline characteristics (group 2). INTERVENTION: Intravesical MMC three times per week for 2 wk for group 1. Transurethral resection of bladder tumor (TUR-BT) and early instillation and a weekly schedule of intravesical MMC for group 2. All cancer-free patients underwent monthly MMC maintenance. Follow-up included bladder mapping, voiding and washing urinary cytology, TUR of suspected area, TUR of previous tumor location, and ultrasound or computed tomography/magnetic resonance imaging. OUTCOME MEASUREMENT AND STATISTICAL ANALYSIS: We used χ2 and Student's t test for comparison of categorical and continuous variables, respectively. Kaplan-Meier curves were plotted to estimate cancer-free survival. The significance level was set to p<0.05. RESULTS AND LIMITATIONS: The complete response rate at 39 mo was 61.7% in group 1 and 70.2% in group 2 (p=0.38). Kaplan-Mayer analysis revealed no difference in cancer-free survival rates overall (log-rank <3.84), according to tumor size in each group (log-rank <3.84), or between the groups (log-rank <7.82). No cases of systemic toxicity were observed. Local toxicities did not differ between the groups (p=0.32) and resolved on treatment of symptoms, and no patient discontinued their treatment. Limitations include the small number of patients, selection bias because of the single tertiary center, and short follow-up. CONCLUSIONS: The proposed MMC schedule had good ablative power that can be explained by better concordance between the scheduled timing and the tumor cell duplication rate. The short-term intensive schedule could be considered as a therapeutic strategy to replace TUR-BT in selected NMIBC patients. PATIENT SUMMARY: We report our experience of a tailored intravesical therapy schedule for bladder cancer. This schedule could be considered a therapeutic strategy to replace surgery for selected patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Racioppi M, Di Gianfrancesco L, Ragonese M, et al. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2018. PMID: 31411974. doi:10.1016/j.euo.2018.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。